AI–scientist collaboration ↗
An editorial connection between questions, not a claim that the studies demonstrate the same mechanism or outcome.
INSIGHT BANK · 28 LIVING CARDS
Follow a question. See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
Solid lines: sourced relationships. Dashed: editorial relatedness. Select a card to inspect each link; proximity is not importance.
SELECTED CARD
After AI Finds a Candidate, What Gets Paid For? ↗
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
What Does Chugai Still See in a Drug Roche Is Walking Away From? ↗
A business comparison of who holds asset rights and bears development costs.
Investing in another company's drug to advance your own ↗
Joint discovery and therapeutic pretreatment share the question of how contracts reward enabling contributions.
What does an AI business sell when it helps run a clinical trial? ↗
Distinguishes drug rights and trial-service fees from collaborative discovery models.
Does an antibody that binds well make a good development candidate? ↗
Adds application-specific acceptance criteria and comparison methods to the business question of who performs validation.